Literature DB >> 9368553

Pharmacological elevation of blood pressure in acute stroke. Clinical effects and safety.

G Rordorf1, S C Cramer, J T Efird, L H Schwamm, F Buonanno, W J Koroshetz.   

Abstract

BACKGROUND AND
PURPOSE: Lowering of blood pressure can adversely affect ischemic symptoms in acute stroke. The aim of our study was to determine whether induced hypertension in stroke is safe and to examine its effects on neurological deficits in patients presenting with acute cerebral ischemia.
METHODS: We retrospectively reviewed all patients admitted to our neurological intensive care unit with the diagnosis of ischemic stroke over a 2.5-year period. Thirty-three patients were not given a pressor agent (Ph- group), while 30 were treated with phenylephrine (Ph+ group) in an attempt to improve cerebral perfusion.
RESULTS: Baseline characteristics showed few differences between the Ph+ and Ph- groups. Intracerebral hemorrhage, brain edema, cardiac morbidity, and mortality were not increased in the Ph+ group. In 10 of 30 Ph+ patients, a systolic blood pressure threshold was identified below which ischemic deficits worsened and above which deficits improved. The mean threshold was 156 mm Hg (range, 120 to 190 mm Hg). The mean number of stenotic/occluded cerebral arteries was greater in those Ph+ patients with an identified clinical blood pressure threshold (mean, 2.1 per patient) than in Ph+ patients without a threshold (mean, 1.2 per patient; P < .05).
CONCLUSIONS: The results suggest that careful use of phenylephrine induced hypertension is not associated with an increase in morbidity or mortality in acute stroke. Although based on a retrospective analysis of clinical practice, this report suggests that a subset of patients, particularly those with multiple stenosis of cerebral arteries, may improve neurologically upon elevation of the blood pressure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368553     DOI: 10.1161/01.str.28.11.2133

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  35 in total

Review 1.  Critical care of acute ischemic stroke.

Authors:  R A Bernstein; J C Hemphill
Journal:  Curr Neurol Neurosci Rep       Date:  2001-11       Impact factor: 5.081

2.  Acute Ischemic Stroke.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

Review 3.  Systemic blood pressure and stroke outcome and recurrence.

Authors:  Argye E Hillis
Journal:  Curr Atheroscler Rep       Date:  2004-07       Impact factor: 5.113

Review 4.  Systemic blood pressure and stroke outcome and recurrence.

Authors:  Argye E Hillis
Journal:  Curr Hypertens Rep       Date:  2005-02       Impact factor: 5.369

Review 5.  The contribution of neuroimaging to the study of language and aphasia.

Authors:  Andrew Lee; Vijay Kannan; Argye E Hillis
Journal:  Neuropsychol Rev       Date:  2006-12       Impact factor: 7.444

Review 6.  Role of vasopressor administration in patients with acute neurologic injury.

Authors:  Katie M Muzevich; Stacy A Voils
Journal:  Neurocrit Care       Date:  2009-04-22       Impact factor: 3.210

Review 7.  Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials.

Authors:  Jialing Liu; Yongting Wang; Yosuke Akamatsu; Chih Cheng Lee; R Anne Stetler; Michael T Lawton; Guo-Yuan Yang
Journal:  Prog Neurobiol       Date:  2013-11-27       Impact factor: 11.685

Review 8.  Treatment or prevention of complications of acute ischemic stroke.

Authors:  L J Kappelle; H B Van Der Worp
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

Review 9.  Comparative tolerability profile of hypertensive crisis treatments.

Authors:  E Grossman; A N Ironi; F H Messerli
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

10.  Pharmacologic elevation of blood pressure for acute brain ischemia.

Authors:  Latha G Stead; M Fernanda Bellolio; Rachel M Gilmore; Alyx B Porter; Alejandro A Rabinstein
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.